@atlas I’m happy to share anything. I’m one of the least knowledgeable people on this website, so I just usually lead with, nah, they probably already know this!
I have thus far only pasted a couple paragraphs I have found interesting.
As I go through things, if I find anything I think you might find unique, I’m happy to share, but where? I don’t want to detour too much away from TBI-CHI’s topic.
Also @Nick1 I’m so glad you found it helpful!!! I mentioned I’m always tinkering to improve the project and spent all day on that yesterday. If it seems the updated architecture works better after I test it, I’ll re-share my project instructions and a summary from Claude on what we did… happy to copy and paste my skills and scheduled tasks too… if anyone can avoid any of the time/heartache I’ve put into this, I’m happy to do so!!
EDIT:
@atlas
Here is an example of what Claude shared after I said: “what’s new since sept 12”
Six nights, six for six — research and purpose scans filled every slot from 9/12 through 9/17. 18 components re-verified, 6 purposes scanned. The only BROKEN files are from the 9/6–9/10 outage, already logged as “nothing to do,” and runs have been clean since 9/11.
Weakest point in what follows: my top two items are both title-only — the source pages were blocked — so my ranking could be wrong once they’re actually read.
Touches what you take
- Urolithin A — first reported human kidney stones (case report, NOT VERIFIED — full text blocked). You take it alongside calcium and telmisartan, with kidney monitoring already running. This is the one lead that most needs a real read.
- Progesterone raises free T4 (randomized trial, Sathi 2013, n=31 over 12 weeks). Direct cross-link to Synthroid/T3 with Hashimoto’s, and it isn’t on your record yet.
- Two items both pointing at the paused Livalo: CoQ10 cuts statin muscle pain (meta-analysis, 7 RCTs, n=389 — your 150 mg sits inside the studied range), and statin starters had less cancer in an ASPREE-based analysis (observational, trial-style design) — but it was lipophilic statins specifically, and nobody confirmed which side pitavastatin falls on.
- Lithium orotate’s whole premise is disputed (expert commentary, Br J Psychiatry) — the argument is that orotate dissociates in the stomach and is just lithium. Separately, LATTICE used far less lithium than your record says, so your exposure gap is ~6–10x, not 100x.
- Calcifediol: the VITAL fracture null on your cell explicitly excludes people with osteoporosis — you. And your half-life is ~11 days, not up to 25; the 25 figure is kidney-disease patients.
- Repatha context: pelacarsen (an Lp(a)-lowering drug) missed its cardiovascular endpoint (manufacturer topline, 9/4). Lowering Lp(a) didn’t buy events.
Not in your protocol, genuinely new: oral niacinamide for non-melanoma skin cancer prevention — RCT plus a 33,000-veteran cohort showing 54% fewer new cancers after a first one.
Seven citation corrections are queued for an edit session: AMLA (two), Lithium, Calcifediol, Seeking Health, Urolithin A, Vit C, Blueprint Essentials.
